Drug Profile
Scopolamine - Repurposed Therapeutics
Alternative Names: DPI-385-CVS; DPI-386; DPI-386 Nasal Gel; DPI-386-SG; DPI-386-SS; DPI-387; DPI-521-CG; DPI-550-TBI; INSCOP spray; Scopolamine HBr - Repurposed TherapeuticsLatest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Epiomed Therapeutics
- Developer National Aeronautics and Space Administration; Repurposed Therapeutics
- Class Antidepressants; Antiemetics; Antispasmodics; Hypnosedatives; Mydriatics; Small molecules; Tropanes
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Motion sickness
- Phase II Familial cyclic vomiting syndrome
- Phase I Bipolar depression; Chemically-induced disorders; Depressive disorders; Major depressive disorder
- Preclinical Traumatic brain injuries; Unspecified
Most Recent Events
- 30 Jan 2024 Defender Pharmaceuticals intends to schedule a formal meeting with the US FDA to fully understand the issues raised in the Complete Response Letter (CRL), as well as develop and implement a comprehensive action plan
- 30 Jan 2024 Defender Pharmaceuticals receives complete response letter from the US FDA for Motion sickness (Prevention, In adults) (Intranasal)
- 26 Sep 2023 Defender plans for Launh of scopolamine for Motion sickness (Prevention) in USA (Intranasal)